Stem-Cell Clinical Trials offered for Acute Myelogenous Leukemia

Phase I Study of Alemtuzumab, Low-Dose Total Body Irradiation, and Fludarabine Followed By HLA Class I Mismatched Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Malignancies.
AML patients up to 74 years old will be eligible to receive immunotherapy, radiation, and chemotherapy treatment followed by peripheral stem cell transplantation. This trial is located in CA, CO, TX, UT, WA, and WI. READ MORE

Phase I/II Evaluation of Safety and Activity of Mylotarg plus Melphalan and [s] Fludarabine as Preparative Therapy for Older or Medically Infirm Patients Undergoing Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation.
AML patients between the ages of 55 and 75 who are currently undergoing allogenic bone marrow and/or peripheral blood stem cell transplantation are eligible. The trial is testing the effectiveness and best dose for a drug therapy program designed to prevent transplantation side effects. This is located at the MD Anderson Cancer Center in Houston, TX. READ MORE

Megadose CD34 Selected Progenitor Cells for Transplantation in Patients with Advanced Hematological Malignant Diseases.
AML patients between the ages of 18 and 60 are eligible for this trial, which is exploring the feasibility and success rate of purified CD34 progenitor cell transplants for patients with hematological malignancies like AML. This trial is located at the MD Anderson Cancer Center in Houston, TX. READ MORE

Phase II Study of Immunosuppression Comprising Tacrolimus and Mycophenolate Mofetil for Graft-Versus-Host Disease Prevention After Nonmyeloablative Conditioning Comprising Total Body Irradiation With or Without Fludarabine and Allogeneic Stem Cell Transplantation in Patients With Hematologic Malignancies.
AML patients who are up to 74 years old will be able to participate in an investigation of how effectively new chemotherapy drugs treat certain side effects of stem cell transplantation. This trial is located in CA, CO, GA, OR, TX, UT, WA, and WI. READ MORE

National Marrow Donor Program Protocol for Filgrastim-Mobilized Peripheral Blood Stem Cells for Primary Allogenic Transplanation with Unrelated Donors.
This trial’s purpose is to see if stem cells from the blood can be used in place of bone marrow cells for treating leukemias such as AML. This trial is located at the City of Hope National Medical Center in Duarte, CA. READ MORE

Phase II Study of IV Busulfan Combined with 12 cGy of Fractionated Total Body Irradiation (FTBI) and Etoposide (VP-16) as a Preparative Regimen for Allogeneic Bone Marrow Transplantation for Patients with Advanced Hematological Malignancies.
This trial is for patients between 16 and 55 years of age. Only AML patients that do not respond to chemotherapy are eligible. The effects of Busulfan and Etoposide combined with total body irradiation as a preparation for bone marrow transplantation for treating AML with be tested. This trial is located at the City of Hope National Medical Center in Duarte, CA. READ MORE

Phase II Window Evaluation of the Farnesyl Transferase Inhibitor (R115777) Followed by 13-CIS Retinoic Acid, Cytosine Arabinoside and Fludarabine Plus Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytis Leukemia (CCG-AAML0122).
This trial is for children with AML and is studying the effectiveness of new chemotherapy drugs and with follow that trial with conventional chemotherapy and stem cell transplantation for younger leukemia patients. It is located at the UCLA Jonsson Comprehensive Cancer Center in Los Angeles, CA. READ MORE

Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy With or Without Arsenic Trioxide (AS203) as Initial Consolidation Therapy Followed by Intermittent Tretinoin Maintenance Therapy (CCG 9710).
This trial is studying particular combinations of chemotherapy drugs and procedures to more effectively treat acute leukemias like AML. It is located at the UCLA Jonsson Comprehensive Cancer Center in Los Angeles, CA. READ MORE

Pilot Trial of Two Dose Levels of Thymoglobulin as part of a Myeloablative-Conditioning for a HLA Identical Matched Related Donor (MRD) Stem Cell Transplant (SCT) with Cyclosporine (CsA) as Posttransplantal Graft vs. Host Disease (GvHD) Prophylaxis.
AML patients who have already had a particular stem cell transplantation and are between the ages of 18 and 55 are eligible for this trial. The trial is testing certain drugs that may prevent common side effects of stem cell procedures and is located at the UCLA Jonsson Comprehensive Cancer Center in Los Angeles, CA. READ MORE

Phase II Study of a Nonmyeloablative Preparative Regimen Comprising Fludarabine and Busulfan Followed By Allogeneic Stem Cell Transplantation in Older Patients With Acute Myeloid Leukemia in First Complete Remission.
This trial will test the effectiveness of drug therapy before stem cell transplantation in patients between 60 and 74 years old who have AML. This trial is located in AL, CA, DE, DC, FL, IL, IN, IO, KY, ME, MD, MA, MI, MN, MO, NE, NV, NH, NJ, NY, NC, OH, OK, PA, RI, SC, TN, TX, VT, VA, WV, and WI. READ MORE

Phase II Study of Allogeneic Peripheral Blood Stem Cell Transplantation With Pre-Conditioning Low-Dose Total Body Irradiation and Fludarabine Followed By Mycophenolate Mofetil and Cyclosporine in Elderly Patients With Acute Myeloid Leukemia in First Complete Remission.
The effectiveness of chemotherapy and total body irradiation preceding stem cell transplantation for AML patients between the ages of 55 and 69 years is being tested. This trial is located in AZ, AR, CA, CO, FL, GA, HI, ID, IL, IN, KS, KY, LA, MA, MI, MS, MO, MT, NM, NY, OH, OK, OR, SC, TN, TX, UT, and WA. READ MORE

Phase III Randomized Study of Induction Chemotherapy Followed By Cytogenetic Risk-Adapted Intensification Therapy Followed By Interleukin-2 Versus No Further Therapy in Patients With Previously Untreated Acute Myeloid Leukemia.
AML patient between the ages of 15-59, will be given chemotherapy along with stem cell transplantation treatment, and other cancer drugs treatment. This trial is located in AL, CA, DE, DC, FL, IL, IN, IA, KY, MD, MA, MI, MN, MO, NE, NV, NH, NJ, NY, NC, OH, OK, RI, TX, VT, VA, and WV. READ MORE

Phase III Randomized Study of Filgrastim (G-CSF)-Mobilized Peripheral Blood Stem Cell Transplantation Versus Bone Marrow Transplantation From HLA-Compatible Unrelated Donors in Patients With Hematologic Malignancies.
This trial is for AML patients are up to 66 years old and will be investigating the benefits and disadvantages of stem cell transplantation compared to bone marrow transplantation. This trial is located in AZ, CA, DC, FL, GA, IL, IN, IA, MD, MA, MI, MN, MO, NE, NJ, NY, NC, OH, OK, OR, PA, TN, TX, UT, VA, and WA. READ MORE

Phase II Study of Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Relapsed Hematologic Malignancies After Prior High-Dose Chemotherapy and Autologous Stem Cell Transplantation.
This trial is for AML patients who are up to 69 years old who previously had chemotherapy and autologous stem cell transplantation but have relapsed. The trial will employ allogenic bone marrow transplantation and peripheral stem cell transplantation. This study is located in AL, CA, DE, DC, FL, IL, IN, IA, KY, MD, MA, MI, MN, MO, NE, NV, NH, NJ, NY, NC, OH, OK, PA, RI, TX, VT, VA, and WV. READ MORE

Phase I Study of a Reduced Intensity Conditioning Regimen Comprising Alemtuzumab, Fludarabine, Melphalan, and Thiotepa Followed by Allogeneic Peripheral Blood Stem Cell Transplantation and LMB-2 Immunotoxin-Treated, Selectively-Depleted Donor T Cells in Patients With Hematologic Malignancies.
AML patients between the ages of 18 and 55 may participate in an investigation on the best dose of donor lymphocytes in a stem cell transplantation following immunotherapy and chemotherapy. This trial is located at the Yale Comprehensive Cancer Center in New Haven, CT. READ MORE

Phase II Study of Allogeneic Mixed Chimerism Peripheral Blood Stem Cell Transplantation Utilizing In Vivo and In Vitro Alemtuzumab (Monoclonal Antibody CD52; Campath-1H) in Patients With High-Risk Hematologic Malignancies or Refractory Breast or Renal Cell Cancer or Melanoma.
AML patients who are at least 18 years old may take part in an investigation of how well stem cell transplantation and monoclonal antibody therapy treats AML. This trial is located in FL and NC. READ MORE

Ex Vivo Selective Depletion of Alloreactive Donor T-Lymphocytes Utilizing RFT5-SMPT-dgA, a Specific Anti-Interleukin-2 Receptor Immunotoxin: Reducing GVHD Risk Associated with HLA-Matched Nonmyeloablative Peripheral Blood Stem Cell Transplantation.
AML patients who are at least 18 years old may participate in this trial of a experimental form of stem cell transplantation. This trial is located at the National Heart, Lung and Blood Institute in Bethesda, MD. READ MORE

A Safety Study of Infusion of Ex Vivo Selectively Amplified Unrelated Cord Blood Stem Cells in Subjects with Hematological malignancies Receiving Unrelated Cord Blood Transplantation.
AML patients between the ages of 12 and 60 may participate in this trial that is studying the effectiveness of stem cell infusions as a replacement for transplantations when treating leukemias like AML. This trial is located in MN, NJ, and OH. READ MORE

Phase II Study of Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation in Older Patients With De Novo or Secondary Acute Myeloid Leukemia in First Complete Remission.
AML patients who are at least 55 years old may participate in this trial which is studying how well stem cell transplantations work for older AML patients. This trial is located in OR, UT, and WA. READ MORE

Phase II Study of Busulfan and Etoposide Followed by Autologous or Syngeneic Stem Cell Rescue and Low-Dose Interleukin-2 in Patients With Acute Myelogenous Leukemia.
AML patients up to 65 years old may participate in this trial which is studying the effectiveness of chemotherapy followed by stem cell transplantation for AML cases. This trial is located in Seattle, WA. READ MORE

Phase I/II Study of Immunologically Engineered, Filgrastim (G-CSF)-Mobilized, Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia Transformed From MDS, or Myeloproliferative Disorders.
AML patients who are between the ages of 18 and 55 may participate in this trial which is studying the effectiveness of stem cell transplantation for AML. This trial is located at the Fred Hutchinson Cancer Research Center in Seattle, WA. READ MORE

Phase I Pilot Study of Nonmyeloablative Conditioning Comprising Fludarabine and Low-Dose Total Body Irradiation Followed by Allogeneic Hematopoietic Stem Cell Transplantation and Graft-Versus-Host Disease Prophylaxis Comprising Mycophenolate Mofetil and Cyclosporine in Patients With Fanconi's Anemia.
There are no age or gender restrictions for this trial, where the side effects and proper dosage for total-body irradiation along with chemotherapy are being investigated. This trial is located in IL, IN, UT, and WA. READ MORE

Sources

ClinicalTrials.gov, www.clinicaltrials.gov

Center Watch—Clinical Trials Listing Service, http://www.centerwatch.com/patient/studies/cat92.html

UCLA Health Sciences, http://www.cancer.mednet

Mayo Clinic, http://clinicaltrials.mayo.edu/